Welcome to our dedicated page for Seelos Therapeutics news (Ticker: SEEL), a resource for investors and traders seeking the latest updates and insights on Seelos Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Seelos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Seelos Therapeutics's position in the market.
Seelos Therapeutics (Nasdaq: SEEL) has initiated a preclinical study for SLS-004, targeting Parkinson’s disease (PD) via a lentiviral vector aimed at regulating the alpha-synuclein (SNCA) gene. This bimodular viral system creates a method for both activation and repression of PD-related pathologies. Previous findings indicated that SLS-004 could effectively repress SNCA expression, addressing a significant risk factor in PD. The early commencement of this study is viewed as a pivotal advancement in Seelos' gene therapy program.
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, will participate in the Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference on June 15-16, 2020. Raj Mehra, Ph.D., Chairman and CEO, will host meetings through conference calls. Seelos focuses on developing therapies for central nervous system disorders and rare diseases, with a portfolio targeting conditions like Acute Suicidal Ideation in Major Depressive Disorder and Parkinson’s Disease.
Seelos Therapeutics (Nasdaq: SEEL) has appointed Judith Dunn, Ph.D., to its Board of Directors, enhancing its leadership in the biopharmaceutical sector. Dr. Dunn has a robust career, previously serving roles at F. Hoffman-La Roche and Pfizer, where she held key positions in clinical development. Her experience spans over two decades in psychiatry and neurology, expected to strengthen Seelos' capabilities. Raj Mehra, CEO, expressed confidence in her contributions, viewing her as an invaluable resource for the company.
Seelos Therapeutics (Nasdaq: SEEL) has announced that the FDA granted Rare Pediatric Disease Designation (RPDD) to its therapy SLS-005 for Sanfilippo syndrome. This designation incentivizes the development of treatments for rare pediatric diseases, which could lead to priority review vouchers (PRVs) for future applications. Additionally, SLS-005 also received Orphan Disease Designation from the FDA. These designations are part of the FDA's efforts to encourage innovation in the treatment of rare conditions.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in the Jefferies Virtual Healthcare Conference from June 2-4, 2020. Raj Mehra, Ph.D., Chairman and CEO, will conduct one-on-one meetings via conference calls. Seelos is focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio targeting major conditions including Major Depressive Disorder, PTSD, and Sanfilippo syndrome. For more details on the conference and Seelos' initiatives, visit their website.
Summary not available.
Summary not available.